Home
News
Screeners
Insights
Norris Medicines
14.
26
0.00
(0.00%)
Market Cap
₹14.30 Cr
PE Ratio
-50.93
Industry
Commercial Services
Buy
Sell
Company Performance:
1D
0.00%
1M
+5.16%
6M
+0.42%
1Y
-11.15%
5Y
+70.37%
View Company Insights
Latest news about Norris Medicines
Norris Medicines Appoints Iqubal Ismail Patel as CFO and KMP
3 days ago
Norris Medicines Limited appointed Iqubal Ismail Patel as Chief Financial Officer and Key Managerial Personnel effective July 30, 2026, with Board approval granted on the same date following recommendations from the Audit Committee and Nomination and Remuneration Committee. Patel, a Graduate with over 11 years of association with the company, brings expertise in finance, accounts, taxation, budgeting, and financial planning, ensuring continuity in the company's financial strategy and governance.
Norris Medicines narrows FY26 net loss to ₹28.06 lakh
May 30, 2026
Norris Medicines Limited Announces Q3 FY26 Financial Results
Feb 14, 2026
Norris Medicines Independent Director Ms. Sathya Venkatachalam Resigns Due to Personal Reasons
Dec 12, 2025
Norris Medicines Successfully Completes NAFDAC Regulatory Audit in Nigeria
Dec 12, 2025
More news about Norris Medicines
11
Dec 25
Bombay High Court Allows Norris Medicines' Criminal Appeal, Sets Aside ₹1.33 Crore Deposit Order
Norris Medicines Limited has won a significant legal victory with the Bombay High Court allowing Criminal Appeal No. 89 of 2020 and setting aside a deposit requirement of ₹1,32,92,359 plus 18% interest under the Maharashtra Protection of Interest of Depositors Act. The court ruled that since the related MPID Special Case No. 3 of 2003 resulted in acquittal, the original deposit order could not be sustained, rendering it infructuous and eliminating the financial obligation for the pharmaceutical company.
15
Nov 25
Norris Medicines Reports Q2 FY26 Loss of Rs 102.86 Lakhs Amid Operational Challenges
Norris Medicines released unaudited financial results for Q2 FY2025-26, reporting a net loss of Rs 102.86 lakhs and revenue from operations of Rs 200.04 lakhs. The company's financial position shows strain with total assets at Rs 1,348.14 lakhs and negative other equity of Rs 2,582.19 lakhs, indicating significant accumulated losses. The Board of Directors approved these results on November 14, 2025, in compliance with SEBI regulations.
Norris Medicines
14.
26
0.0
(0.0%)
1 Year Returns:
-11.15%
Industry Peers
Redington
321.65
(+
3.
44
%)
MMTC
62.66
(+
4.
28
%)
MSTC
618.20
(+
2.
22
%)
Ravindra Energy
167.98
(-
1.
66
%)
BN Agrochem
279.00
(+
1.
82
%)
Elitecon International
15.64
(-
0.
64
%)
Vintage Coffee & Beverages
149.48
(+
0.
95
%)
Creative Newtech
993.20
(-
0.
40
%)
TCC Concept
289.65
(+
1.
15
%)
RRP Defense
(0.0%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar